TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 170 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,270,473 | -32.4% | 813,252 | +16.2% | 0.00% | -33.3% |
| Q2 2023 | $10,752,031 | -13.1% | 700,002 | +27.2% | 0.00% | 0.0% |
| Q1 2023 | $12,379,755 | +5.7% | 550,456 | -1.1% | 0.00% | 0.0% |
| Q4 2022 | $11,706,896 | +8.6% | 556,676 | +27.2% | 0.00% | 0.0% |
| Q3 2022 | $10,783,000 | -10.9% | 437,586 | -12.4% | 0.00% | -25.0% |
| Q2 2022 | $12,103,000 | +17.6% | 499,486 | +25.1% | 0.00% | +33.3% |
| Q1 2022 | $10,292,000 | -35.1% | 399,357 | -21.9% | 0.00% | -25.0% |
| Q4 2021 | $15,868,000 | +1669.0% | 511,201 | +1282.7% | 0.00% | – |
| Q3 2021 | $897,000 | +80.5% | 36,972 | +8.4% | 0.00% | – |
| Q2 2021 | $497,000 | -94.9% | 34,104 | -91.3% | 0.00% | -100.0% |
| Q1 2021 | $9,765,000 | +1088.0% | 391,091 | +1196.6% | 0.00% | – |
| Q4 2020 | $822,000 | – | 30,163 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |